AstraZeneca vaccine halted in Canada, three German cities amid blood clot worry – New York Post
Canada and three German cities are no longer recommending the AstraZeneca COVID-19 vaccine to young people amid reports the inoculation is causing serious blood clots in some recipients, reports and officials said Tuesday.
Canada’s National Advisory Committee on Immunization recommended Monday the British-made vaccine shouldn’t be given to people under the age of 55 while Berlin, Munich and Bradenburg have suspended the shot for people under the age of 60.
“NACI recommends that AstraZeneca COVID-19 vaccine should not be used in adults under 55 years of age at this time while the safety signal of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) following vaccination with AstraZeneca COVID-19 vaccine is investigated further,” Canadian officials wrote in a statement.
Eight of Canada’s ten provinces, including large locales like Ontario and Quebec, confirmed they are no longer giving the AstraZeneca jab to people under 55 years of age following NACI’s recommendation, Insider reported.
While the three German cities have already stopped the jab for people under 60, the entire country is considering pulling the plug, according to a draft resolution from Germany’s Standing Vaccination Commission, obtained by local outlet Der Tagesspiegel.
The draft recommends no one under the age of 60, both male and female, receive the AstraZeneca vaccine but the use below that limit “remains possible at the medical discretion and after careful clarification, if the individual risk is accepted,” the outlet reported.
“Although significantly more women were affected, the Stiko restricts its recommendation for both sexes as a precaution.”
The commission hopes to come to an agreement on the country-wide plan moving forward by Tuesday evening.
While the vaccine-induced blood clots appear to be rare, health officials have found it tends to impact younger people more, CTV reported.
The AstraZeneca vaccine — which has become a key weapon in Europe’s battle to immunize its residents against the coronavirus — has yet to be approved for use in the US and is about 76 percent effective, the company said.
The company maintains the vaccine is safe and released a statement in mid-March saying a review of safety data from more than 17 million people who received the jab in the UK and the European Union found no evidence of a higher risk for pulmonary embolism or deep vein thrombosis, conditions associated with blood clots.